NMT-cNP8
NeoMatrix Therapeutics: NMT- cNP8 (IV & Topical Therapy)
​
NMT-cNP8 is a novel, bioactive peptide for intravenous and topical treatment of burns within 8 to 24 hours post-injury. NMT-cNP8 has the potential to limit burn injury progression, shorten healing time, and reduce scarring of acute, deep burns.
NMT-cNP8 was engineered by NeoMatrix to serve as both a topical and an IV treatment for severe burns. Like NMT-cP12, NMT- cNP8 promotes mesenchymal cell growth, proliferation and migration in vitro and acts synergistically with a variety of growth factors including platelet-derived growth factor-BB. However, unlike NMT-cP12, NMT-cNP8 is effective topically because it resists both exopeptidases as well as neutrophil elastase, which are known to play a major role in Fibronectin degradation in burn wound fluid. NMT-cNP8 may be used independently or in combination with NMT-cP12.
​
Development Plans
​
NMT filed an IND for NMT-cNP8 in November, 2022 and received FDA consent that we could proceed in December, 2022.
NMT was awarded a contract for a IV cNP8 Phase 1 Clinical Trial in October, 2023 and the Clinical Trial was successfully completed in July, 2024.
NMT will be meeting with the FDA within the next couple months for a End of Phase 1 (EoP1) to map a plan for the Phase 2 Clinical Trial.
In addition, NMT has developed a successful topical delivery system for cNP8 on burn wounds in a Yorkshire pig.
References:
Macri LK, et al., J Contr Rel 161:813-820, 2012.